Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta
Georgia
30005
United States
Tel: 678-270-3631
Fax: 678-270-4033
Website: http://www.clearsidebio.com/
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and nonclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Stock Symbol: CLSD
Stock Exchange: NASDAQ
179 articles about Clearside Biomedical, Inc.
-
Clearside Biomedical’s Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery
9/9/2020
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licensing partner, REGENXBIO Inc. (Nasdaq: RGNX), has dosed the first patient in its Phase 2 clinical trial to evaluate the suprachoroidal delivery of RGX-314, an adeno-associated virus (AAV) gene therapy, using Clear
-
Clearside Biomedical to Present at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference
9/9/2020
Clearside Biomedical, Inc. (NASDAQ:CLSD), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 11:30 a.m. ET.
-
Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe- New intellectual property covers suprachoroidal administration with therapeutic agents including CLS-AX and XIPERE -
8/26/2020
Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced the recent issuance of three additional patents in the United States and Europe.
-
Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space
8/10/2020
Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020
-
Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update
8/10/2020
Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, reported financial results for the second quarter ended June 30, 2020 and provided a corporate update on key initiatives.
-
Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
8/4/2020
Clearside Biomedical, Inc. announced that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 a.m. ET.
-
Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020
7/30/2020
Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that its second quarter 2020 financial results will be reported on Monday, August 10, 2020 after the close of the financial markets.
-
Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual Meeting
7/27/2020
Clearside Biomedical, Inc. announced that multiple posters and oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector® targeting the suprachoroidal space were delivered at the American Society of Retina Specialists 2020 Virtual Annual Meeting.
-
Clearside Biomedical Announces Numerous Presentations at the ARVO 2020 Meeting
6/17/2020
Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration
-
Clearside Biomedical Announces First Quarter 2020 Financial Results
5/8/2020
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended March 31, 2020. “Our team remains focused on progressing our programs as we navigate the evolving business and regulatory environment,” said George Lasezkay, Pharm.D., J.D., Presiden
-
Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health
4/28/2020
Management to Host Webcast and Conference Call Today at 8:30 A.M. ET
-
Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors- Pfizer veteran brings global R&D expertise to Board of Directors -
4/22/2020
Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that Nancy J. Hutson, Ph.D. has been appointed to the Company's Board of Directors, effective April 21, 2020..
-
Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians
4/9/2020
Clearside Biomedical, Inc. announced the formation of a Scientific Advisory Board comprised of world-renowned retinal physicians to advise on the Company’s research and development programs.
-
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
4/8/2020
Clearside Biomedical, Inc. announced that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the Needham Virtual Healthcare Conference on April 15, 2020 at 12:00 p.m.
-
Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer
3/11/2020
Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., has been appointed President and Chief Executive Officer
-
Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South Korea
3/11/2020
Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, has acquired an exclusive license for the commercialization and development of XIPERE
-
Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
3/11/2020
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the fourth quarter and year ended December 31, 2019 and provided a corporate update.
-
Clearside Biomedical to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update on Wednesday, March 11, 2020
2/27/2020
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its fourth quarter and full year 2019 financial results will be reported on Wednesday, March 11, 2020 after the close of the financial markets.
-
Clearside Biomedical to Present at Two Upcoming Investor Conferences in March 2020
2/26/2020
ALPHARETTA, Ga., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will present at two upcoming investor conferences in March 2020: Cowen 40th Annual Health Care Conference Company Presentation: Wednesday, March 4, 2020 at 8:00 am ET Boston, MA 32nd Annual ROTH Conference P
-
Clearside Biomedical Pipeline Highlighted in Oral Presentations at the Annual Angiogenesis and Macula Society Meetings
2/25/2020
Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector™ targeting the suprachoroidal space were given this month at the 17th Annual Angiogenesis Meeting and 43rd Annual Macula Society Meeting.